Abstract
Urinary incontinence, although rarely reported, is one of the most important adverse effects of antipsychotic medication. It can be an embarrassing, distressing, and potentially treatment-limiting. Several antipsychotics, including both typical and atypical varieties, are known to induce urinary incontinence. Many antipsychotic drugs target the neural pathways controlling continence by binding to receptors of some neurotransmitters such as serotonin, dopamine, acetylcholine, and adrenaline. Pharmacological management of incontinence should be considered if there is a risk of cessation of the antipsychotic therapy or any decline in patients' compliance. Amitriptyline, desmopressin, ephedrine, and anticholinergics such as oxybutynin and trihexyphenidyl are the most frequently used agents to treat incontinence. We think that the frequency of incontinence is higher than reported in the literature, and that follow-up routines should include a form of standardized screening for all possible adverse effects, including incontinence, of any given antipsychotic. In this article, we report a case of urinary incontinence as an adverse effect of paliperidone palmitate use during maintenance therapy in a patient with schizophrenia.
References
Oct 1, 1980·The American Journal of Psychiatry·P J Ambrosini, H G Nurnberg
Jul 1, 1983·Urology·H G Kiruluta, K Andrews
Oct 1, 1984·Journal of Clinical Psychopharmacology·P J Ambrosini
Jan 1, 1981·The American Journal of Psychiatry·A K Shapiro
Feb 1, 1994·Psychopharmacology·L E van BeijsterveldtJ J Heykants
Mar 1, 1995·The American Journal of Psychiatry·J S AronowitzJ A Lieberman
Mar 1, 1996·International Clinical Psychopharmacology·M PoyurovskyA Weizman
Mar 1, 1996·Psychopharmacology·A SchotteJ E Leysen
Nov 1, 1996·The Journal of Clinical Psychiatry·M A FullerP E Konicki
Jan 10, 1998·The Journal of Clinical Psychiatry·S N Lurie, C Hosmer
Oct 3, 2001·BMC Pharmacology·P L VeraI Nadelhaft
Sep 20, 2005·The Australian and New Zealand Journal of Psychiatry·Shanthi SarmaAaron D J Frost
Mar 28, 2006·Schizophrenia Research·Joshua T KantrowitzCenk Tek
Oct 3, 2006·The Urologic Clinics of North America·Karl J Kreder
Feb 19, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Christian DolderZachariah Deyo
Jul 9, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Dattatreya Mendhekar, Deep Lohia
Mar 26, 2009·Expert Opinion on Drug Delivery·Luca Pani, Giorgio Marchese
Sep 4, 2009·Clinical Pharmacokinetics·Mahesh N SamtaniKim Stuyckens
May 28, 2010·The British Journal of Psychiatry. Supplement·W Wolfgang Fleischhacker
Nov 6, 2009·International Journal of Clinical Practice·L Citrome
Nov 11, 2009·Indian Journal of Medical Sciences·Ashish AggarwalR C Jiloha
Nov 28, 2009·The International Journal of Neuropsychopharmacology·Michelle KramerMariëlle Eerdekens
Dec 5, 2009·Schizophrenia Research·David HoughMariëlle Eerdekens
Dec 18, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·D N Mendhekar, C Andrade
May 18, 2010·Journal of Clinical Psychopharmacology·Gahan J PandinaJoseph Palumbo
Jun 18, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Henry A NasrallahDavid Hough
Jul 10, 2010·Journal of Psychopharmacology·S GopalD Hough
Sep 22, 2010·Neuropsychiatric Disease and Treatment·Delia Bishara
Nov 26, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gahan PandinaGeorge Simpson
May 17, 2011·BMC Psychiatry·Cynthia A BossieLarry Alphs
Jun 10, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Mira Harrison-WoolrychDavid C G Skegg
Jan 5, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Thomas R E BarnesCarol Paton
Mar 30, 2012·BMC Psychiatry·Danielle CoppolaGahan Pandina
Sep 12, 2012·Schizophrenia Bulletin·Abraham M Nussbaum, T Scott Stroup